I'll go back the simple negative-case, EPS-based a
Post# of 36537
(Total Views: 189)
Posted On: 10/23/2019 11:24:01 AM
I'll go back the simple negative-case, EPS-based analysis I've done a couple of times:
Let's say the price stays at $1.80, we get our divs, and it dives to $0.90. Share count goes to 70MM.
Trading at 15x earnings. That's 6 cents a year, 1.5 cents a Q. If we have trouble pulling in more than 1.5 cents per Q ($1.05MM!!!) a year from now, it has hit the fan, and we're probably folding up shop.
Or major revs start to show, and the company is perceived as a viable growth story. Trading at 20x, we need a little over $2.5MM/Q to support a $3 stock price.
I don't know what the actual path will be, but this helps show HOW VERY LITTLE they need to get on the rails to get the kind of share value we are looking for to uplist.
I've got a lot in on this, but if it goes much lower before div, I will probably add a bit more here and there.
Let's say the price stays at $1.80, we get our divs, and it dives to $0.90. Share count goes to 70MM.
Trading at 15x earnings. That's 6 cents a year, 1.5 cents a Q. If we have trouble pulling in more than 1.5 cents per Q ($1.05MM!!!) a year from now, it has hit the fan, and we're probably folding up shop.
Or major revs start to show, and the company is perceived as a viable growth story. Trading at 20x, we need a little over $2.5MM/Q to support a $3 stock price.
I don't know what the actual path will be, but this helps show HOW VERY LITTLE they need to get on the rails to get the kind of share value we are looking for to uplist.
I've got a lot in on this, but if it goes much lower before div, I will probably add a bit more here and there.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼